Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,904 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Axatilimab in Recurrent or Refractory Chronic Graft-versus-Host Disease.
Wolff D, Cutler C, Lee SJ, Pusic I, Bittencourt H, White J, Hamadani M, Arai S, Salhotra A, Perez-Simon JA, Alousi A, Choe H, Kwon M, Bermúdez A, Kim I, Socié G, Chhabra S, Radojcic V, O'Toole T, Tian C, Ordentlich P, DeFilipp Z, Kitko CL; AGAVE-201 Investigators. Wolff D, et al. Among authors: tian c. N Engl J Med. 2024 Sep 19;391(11):1002-1014. doi: 10.1056/NEJMoa2401537. N Engl J Med. 2024. PMID: 39292927 Clinical Trial.
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I study.
Berton D, Pautier P, Lorusso D, Gennigens C, Gladieff L, Kryzhanivska A, Bowman J, Tian C, Cornfeld M, Van Gorp T. Berton D, et al. Among authors: tian c. Gynecol Oncol. 2024 Jul;186:191-198. doi: 10.1016/j.ygyno.2024.05.025. Epub 2024 Jun 1. Gynecol Oncol. 2024. PMID: 38824752 Free article. Clinical Trial.
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S, Saunders MP, Gilbert DC, Jensen LH, Samalin E, Spindler KL, Tamberi S, Demols A, Guren MG, Arnold D, Fakih M, Kayyal T, Cornfeld M, Tian C, Catlett M, Smith M, Spano JP. Rao S, et al. Among authors: tian c. ESMO Open. 2022 Aug;7(4):100529. doi: 10.1016/j.esmoop.2022.100529. Epub 2022 Jul 8. ESMO Open. 2022. PMID: 35816951 Free PMC article. Clinical Trial.
Associations of systemic inflammation and systemic immune inflammation with serum uric acid concentration and hyperuricemia risk: the mediating effect of body mass index.
Zhang Y, Han S, Duan Z, Tian X, Li X, Hou G, Gao X, Tian C, Li X, Yu W, Zhou Q, Niu Z, Wang F. Zhang Y, et al. Among authors: tian c. Front Endocrinol (Lausanne). 2024 Dec 9;15:1469637. doi: 10.3389/fendo.2024.1469637. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39720251 Free PMC article.
De novo discovery of bicycles.
Kong XD, Tian C. Kong XD, et al. Among authors: tian c. Nat Chem Biol. 2025 Jan;21(1):29-31. doi: 10.1038/s41589-024-01798-9. Nat Chem Biol. 2025. PMID: 39719493 No abstract available.
4,904 results